Navigation Links
Lilly Declares Second-Quarter Dividend
Date:4/21/2008

INDIANAPOLIS, April 21 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2008 of $0.47 a share on outstanding common stock. This is the same dividend as was paid in the first quarter and maintains the annual indicated dividend rate for 2008 of $1.88 per share.

The dividend is payable June 10, 2008, to shareholders of record at the close of business on May 15, 2008.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com . F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
2. Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement
3. Lilly Sets Date and Conference Call for First Quarter 2008 Financial Results Announcement
4. State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
5. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
6. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
7. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
8. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
9. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
11. Michael L. Eskew Elected to Lilly Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vodori, ... Flow promotional review platform at the Promotional Review Committee Compliance and Best ... marketers streamline the medical, legal, and regulatory review (MLR) process – which ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: